Project Grant R01CA311596
Award Date 9/1/26
Completion Date 8/30/31
Dollars Obligated $677K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded the Sloan-Kettering Institute For Cancer Research $731,503 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial of brief behavioral activation for older adult cancer survivors. The research addresses depression among cancer survivors aged 65 and older, a population expected to comprise 73 percent of all cancer survivors by 2040, with up to 35 percent...
- The National Cancer Institute awarded Thomas Jefferson University $312,363 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to assess the feasibility of a remotely-delivered Tai Chi intervention for older gastrointestinal cancer patients experiencing chemotherapy-induced peripheral neuropathy (CIPN). The study addresses CIPN—characterized by numbness, tingling, and pain that impairs physical function and elevates fall risk—in patients aged 65 and above. The research...
- The National Institutes of Health National Center for Complementary and Integrative Health awarded $1,322,441 to the University of California, San Diego on August 11, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213) to conduct a multi-site feasibility study in preparation for a definitive clinical trial randomizing patients with acute pain to battlefield acupuncture, battlefield acupressure, or sham treatment. Acute postoperative pain affects...
- The National Cancer Institute awarded Duke University $668,691 on March 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a randomized controlled trial testing interventions for older women with breast cancer undergoing adjuvant aromatase inhibitor therapy. The award funds a hierarchical 2×2 factorial trial evaluating two interventions: a clinic and provider-level geriatric oncology assessment linked with support for AI therapy (GOAL-AI), and a patient-level...
- The National Center for Complementary and Integrative Health, part of the Department of Health and Human Services National Institutes of Health, awarded Northwestern University $597,375 on August 17, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213) to conduct a multi-site feasibility trial of an embedded mindfulness-based intervention delivered during radiation therapy for prostate cancer. The study, titled SUPPORT-PC (Supporting Utilization and...
- The National Cancer Institute awarded the University of Maryland, Baltimore $598,422 on August 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the molecular mechanisms of anti-estrogen therapy-induced pain in breast cancer patients and develop targeted interventions to prevent discontinuation of life-saving treatment. The research will define the estrogen receptor-EGLN1-HIF1A pathway's necessity and sufficiency in anti-estrogen therapy-induced musculoskeletal...
- The National Cancer Institute awarded the University of Texas Health Science Center at Houston $663,818 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to assess the impact of early physiotherapy on lymphatic dysfunction in breast cancer survivorship through longitudinal measurement of lymphatic dysfunction using quantitative near-infrared fluorescence lymphatic imaging, evaluation of early physical rehabilitation with advanced pneumatic compression on lymphatic...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of Colorado a $656,046 Project Grant on August 1, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial of EASE (Exposure-based Anxiety and Symptom Elimination), a novel behavioral intervention designed to reduce fear of cancer progression (FOP) and cancer-related trauma symptoms in adults with advanced cancer. The five-year...
- The National Cancer Institute awarded $415,257 to the University of Virginia on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop a comprehensive intervention addressing financial toxicity among cancer survivors and caregivers. The award funds a two-year project (July 1, 2026 through June 30, 2028) performed in Charlottesville, Virginia. The intervention will address all domains of financial toxicity—material burden, psychosocial distress, and coping...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded Oregon Health & Science University $544,420 on August 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct a clinical trial testing the efficacy of low-intensity vibration therapy in reducing chemotherapy-induced peripheral neuropathy symptoms and preserving functional mobility in cancer survivors. The research will evaluate whether low-intensity...